ReviewAntimicrobial agents and chemotherapy2015
Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance.
Review in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 467 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
467 citing papers in PubMed, 4 syntheses or guidelines pooled it, 820 citations in OpenAlex.
- Prevalence of genes encoding carbapenem-resistance in Klebsiella pneumoniae recovered from clinical samples in Africa: systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Pooled it
- Prevalence and clonal diversity of carbapenem-resistant Klebsiella pneumoniae causing neonatal infections: A systematic review of 128 articles across 30 countries.PLoS medicine · 2023Pooled it
- Prevalence of carbapenemase-producing Enterobacteriaceae from human clinical samples in Ethiopia: a systematic review and meta-analysis.BMC infectious diseases · 2023Pooled it
- Clonal diversity, virulence factors and antibiotic resistance genes ofOne health (Amsterdam, Netherlands) · 2026Article
- Genomics of multidrug-resistantIJID regions · 2026Article
- From diagnostic dilemma to successful management: Early prosthetic mitral valve endocarditis complicated by splenic infarction caused byRadiology case reports · 2026Article
- Multi-carbapenemase-producing Klebsiella pneumoniae: Genomic characterization and In Vitro evaluation of cefiderocol and novel β-lactam/β-lactamase inhibitor combinations.Molecular biology reports · 2026Article
- Review
- Klebsiella genus as driver of human disease: from infections to non-communicable disorders.Nature reviews. Microbiology · 2026Review
- Carbapenem-ResistantMicroorganisms · 2026Review
- Rectal Surveillance for Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Article
- Clonal dissemination and plasmid plasticity of KPC-3-producing Klebsiella pneumoniae ST512 during a hospital outbreak in Spain.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- A dual-tier plasmid network model underpins the evolutionary success of pandemic Klebsiella pneumoniae ST11.Scientific reports · 2026Article
- Hidden in the community: poly-clonal spread of KPC- or NDM-producing Klebsiella pneumoniae revealed by whole-genome sequencing in Southeastern Brazil.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Emerging Cross-Resistance to Cefiderocol and Ceftazidime-Avibactam in KPC-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- High burden of blaBMC microbiology · 2026Article
- Spatiotemporal genomic analysis and risk assessment of the plasmids carrying blaBMC microbiology · 2026Article
- Emergence, evolution, and global dissemination of antimicrobial resistance: A One Health review.Archives of microbiology · 2026Review
407 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of infections due to Klebsiella pneumoniae has been complicated by the emergence of antimicrobial resistance, especially to carbapenems. Resistance to carbapenems in K. pneumoniae involves multiple mechanisms, including the production of carbapenemases (e.g., KPC, NDM, VIM, OXA-48-like), as well as alterations in outer membrane permeability mediated by the loss of porins and the upregulation of efflux systems. The latter two mechanisms are often combined with high levels of other types of β-lactamases (e.g., AmpC). K. pneumoniae sequence type 258 (ST258) emerged during the early to mid-2000s as an important human pathogen and has spread extensively throughout the world. ST258 comprises two distinct lineages, namely, clades I and II, and it seems that ST258 is a hybrid clone that was created by a large recombination event between ST11 and ST442. Incompatibility group F plasmids with blaKPC have contributed significantly to the success of ST258. The optimal treatment of infections due to carbapenemase-producing K. pneumoniae remains unknown. Some newer agents show promise for treating infections due to KPC producers; however, effective options for the treatment of NDM producers remain elusive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.